3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Burkitt Lymphoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Prostate Cancer Recurrent
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Biphenotypic, Acute
1
Hematologic Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
taxane
1
radium Ra 223 dichloride
1
pertuzumab
1
X-Rays
1
Trastuzumab
1
Taxoids
1
Taxes
1
Steroids
1
Radiotherapy
1
Radiosurgery
1
Radiation
1
Photons
1
Paclitaxel
1
PF-05280014
1
Ontruzant
1
Ogivri
1
Mastectomy, Simple
1
Mastectomy, Segmental
1
Hormones
1
High-Energy Shock Waves
1
Cyclin-Dependent Kinase Inhibitor p18
1
Cyclin-Dependent Kinase Inhibitor p16
1
CT-P6
1
Biopsy
1
Ado-Trastuzumab Emtansine
1
2C4 antibody
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Anatomic Stage IV Breast Cancer AJCC v8
×
Dasatinib
×
30 days
×
Clear all
No trials found.